Situation Around COVID-19 Treatment And Vaccine
On August 23 the Food and Drug Administration (FDA)approved an Emergency Use Authorization (EUA)* for COVID-19 convalescent plasma for patients with COVID-19 treatment. But in…
treatment
Tuberculosis Vulnerability To Antibiotics
On September 16, 2020, the MIT (Massachusetts Institute of Technology) published results of researches, according to which cell that covered with a distinctive array of…
Dapagliflozin Reduces Risk of Kidney Failure
Recently was confirmed, that treatment with dapagliflozin (Farxiga; AstraZeneca) reduced the risk of kidney failure and cardiovascular (CV) or renal death in patients with chronic…
The FDA Approved The Spinal Cord Treatment
The U.S. Food and Drug Administration (FDA) has approved Uplizna injection for intravenous use for the therapy of neuromyelitis optica spectrum disorder (NMOSD) that affects…
The Chemotherapy Optimization: A Medication Trial
A medication trial for the therapy of chemotherapy-induced neutropenia (CIN) has confirmed specific issues. The PROTECTIVE (Study 106) advantage trial discovered that a marine-derived small-molecule…
The Blood Cancer: An Up-To-Date Research
Lymphoma is a variety of blood cancer related conditions, forming from lymphocytes (a type of white blood cell). It has multiple subtypes. A rare subtype,…
COVID Studies Concerns
Two of the world’s heading pharmaceutical journals on Tuesday showed concern about potential flaws in the data and covid studies provided by a little company…
The Antiviral Effect On COVID
Gilead Sciences, Inс has published topline outcomes from the Phase 3 SIMPLE trial in hospitalized sufferers with COVID infection. This open-label research estimated 5-day and…
Care For High-Risk Patients During The Epidemic
The ongoing difficulties of the coronavirus infection 2019 (COVID-19) pandemic are disproportionately hitting practice sufferers with chronic medical diseases, including high-risk patients and communities (such…
FDA Recommendation For Liver Cancer Treatment
On March 10, the Food and Drug Administration (FDA) recommended a union of the checkpoint inhibitors Opdivo (nivolumab) and Yervoy (ipilimumab) for people with exceptional…